Thromb Haemost 1992; 68(06): 672-677
DOI: 10.1055/s-0038-1646342
Original Article
Schattauer GmbH Stuttgart

Recombinant Variants of Tissue-Type Plasminogen Activator Containing Amino Acid Substitutions in the Finger Domain

Hitoshi Yahara
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Keiji Matsumoto
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Hiroyuki Maruyama
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Tetsuya Nagaoka
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Yasuhiro Ikenaka
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Kazuyoshi Yajima
1   The Biochemical Research Laboratories, Kanegafuchi Chemical Industry Co. Ltd., Takasago, Japan
,
Hideharu Fukao
2   The Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan
,
Shigeru Ueshima
2   The Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan
,
Osamu Matsuo
2   The Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan
› Author Affiliations
Further Information

Publication History

Received 06 February 1992

Accepted after revision 21 July 1992

Publication Date:
04 July 2018 (online)

Zoom Image

Summary

Tissue-type plasminogen activator (t-PA) is a fibrin-specific agent which has been used to treat acute myocardial infarction. In an attempt to clarify the determinants for its rapid clearance in vivo and high affinity for fibrin clots, we produced five variants containing amino acid substitutions in the finger domain, at amino acid residues 7–9, 10–14, 15–19, 28–33, and 37–42. All the variants had a prolonged half-life and a decreased affinity for fibrin of various degrees. The 37–42 variant demonstrated about a 6-fold longer half-life with a lower affinity for fibrin. Human plasma clot lysis assay estimated the fibrinolytic activity of the 37–42 variant to be 1.4-fold less effective than that of the wild-type rt-PA. In a rabbit jugular vein clot lysis model, doses of 1.0 and 0.15 mg/kg were required for about 70% lysis in the wild-type and 37–42 variant, respectively. Fibrinogen was degraded only when the wild-type rt-PA was administered at a dose of 1.0 mg/kg. These findings suggest that the 37–42 variant can be employed at a lower dosage and that it is a more fibrin-specific thrombolytic agent than the wild-type rt-PA.

Crossref Cited-by logo
Article Citations